Table 2.

The prevalences of MS according to four MS criteria among patients with hypertension.

MS prevalence	ATP III	Modified ATP III	IDF	JIS
Baseline	57.60%	74.62%	62.80%	84.41%
Follow-up	35.37%	51.10%	49.66%	65.04%

MS: metabolic syndrome, ATP III: the Adult Treatment Panel III (part of the 2001 US Third Report of the National Cholesterol Education Program), Modified ATP III: the 2004 modification of the ATP III for Asian populations, IDF: the 2005 criteria from the International Diabetes Federation, JIS: the 2009 criteria from the Joint Interim Statement.